Bafna Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals Limited has submitted its annual disclosure under Regulation 31(4) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations for the financial year ended March 31, 2025. The disclosure was filed by the promoters — Bafna Mahaveer Chand (on behalf of the promoter group) and SRJR Lifesciences LLP — both of whom have declared that they did not create any encumbrance (pledge, lien, or similar charge) on the shares held by them in the company during the year. This is a routine annual compliance filing required from every promoter and promoter group entity.
This is a neutral-to-slightly positive disclosure for shareholders, as it confirms the promoter group has not pledged any shares or used their holdings as collateral during the year. It reduces the risk of a sudden forced share sale or margin call triggered by a lender. No material impact on stock price is expected from this routine filing.